Total complement 4 (C4) levels, when analysed on the Beckman Array nephelometer, were found to increase in a number of serum specimens [predominantly from patients with hepatitis C virus (HCV) infection] after overnight storage at 4°C. In order to investigate whether the phenomenon of in vitro colddependent activation of complement (CDAC) was the explanation for this increase, paired specimens were collected from 63 patients with HCV infection in tubes with no anticoagulant (serum) and in tubes containing EDTA (which inhibits complement activation). C4 levels increased after overnight storage at 4°C in 33 serum specimens (52%). In contrast, no increase in C4 levels was observed in any of the 63 EDTA specimens. Immuno®xation of intact and activated C4 products con®rmed that complement activation had taken place in the serum specimens in which C4 levels had increased after storage. There was a higher frequency of hepatitis C viraemia (P< 0´0001), HCV antibody positivity (P< 0´05) and the presence of rheumatoid factor (P< 0´05) in the group of patients in whose serum samples CDAC had occurred (n=33) than in the other group (n=30). As a result of our ®ndings on C4 analysis in stored serum specimens, we would recommend potassium EDTA plasma as the specimen of choice for complement analysis on the Beckman Array.
INTRODUCTION
In vitro activation of the classical pathway of complement at a low temperature is known as cold-dependent activation of complement (CDAC) and was ®rst described in the 1970s. 1 This phenomenon was ®rst noted because of discrepancies found between the measured haemolytic complement activity in corresponding serum and plasma specimens (i.e. much lower activity measured in serum compared with plasma) 2 and was subsequently discovered to be associated with cooling the serum in vitro. 1,3±5 The usual features of CDAC include low or absent total haemolytic complement activity (CH50) and low or absent haemolytic complement 4 (C4) activity in chilled serum, whereas these values are normal (i.e. higher) in EDTA plasma (both chilled and at 37°C) and in serum kept at 37°C before analysis. 5±7 Of note, in the various studies undertaken, the concentration of C4 protein as measured by immunoassay remained unchanged. 3±6,8 Cold-dependent activation of complement has been reported to occur in patients with systemic lupus erythematosus (SLE), 4,6 primary renal disease 9 and chronic liver disease. 1±3 More recently, CDAC has been found to be strongly associated with hepatitis C virus (HCV) infection, with reported incidences in patients with HCV infection ranging from 41±89%. 8,10±12 While evaluating the stability of complement assays [total complement 3 (C3) and total C4] on the Beckman Array rate nephelometer (Beckman Coulter Inc, Fullerton CA, USA), we observed that C4 levels increased in a number of serum specimens after overnight storage at 4°C (an average increase of 25%). Levels of C3 increased to a lesser extent (7%) under the same conditions. It was noted that this ®nding was predominantly associated with specimens from patients with HCV infection. In view of the previously reported strong association of CDAC in patients with HCV infection, we investigated whether this was the explanation for the increase seen in C4 levels when analysed on the Beckman Array after storage at 4°C. We also investigated the frequency of this phenomenon in patients with HCV infection and its potential clinical signi®cance in individual patients.
MATERIALS AND METHODS

Subjects
Total C3 and C4 levels were measured, fresh and after overnight storage at 4°C, in paired blood samples collected from 63 patients with HCV infection, in tubes with no anticoagulant (serum) and in tubes containing potassium EDTA [3 mL glass 7´5% K3 EDTA Becton Dickinson tubes (Becton Dickinson, Plymouth, UK)]. Patients were de®ned as having HCV infection by the presence of a positive HCV antibody titre tested by either the Ortho second generation enzyme immunoassay (EIA) method (Ortho Clinical Diagnostics, Amersham, UK) and/or the Chiron RIBA 3´0 method (qualitative immunoblot assay: Chiron, Bayer Diagnostics, Newbury, UK). Paired serum/EDTA specimens sent to our laboratory for routine analysis of cholesterol and full blood count were analysed fresh for total C3 and C4 (n=36), to assess the suitability of EDTA specimens for routine complement analysis on the Beckman Array.
Methods
Total C3 and C4
Total C3 and C4 were measured in serum and EDTA specimens by rate nephelometry on the Beckman Array fresh (within 6 h) and following overnight storage at 4°C ± both times of analysis ful®lling the conditions recommended by the manufacturer. The method employed in the Beckman Array assays measures the peak rate of increase in light scattered from particles suspended in solution as a result of complexes formed during antigen±antibody reactions. All analyses were carried out as recommended by the manufacturer with no modi®cations.
Activated C3 and C4
The relative amounts of intact and activated C3 and C4 products in fresh and stored serum specimens were assessed by immuno®xation, which was carried out as described by Whicher et al. 13 in combination with the Beckman Paragon IFE system. Specimens had EDTA added (to a ®nal concentration of 0´05 mol/L EDTA in the case of C3 and to a ®nal concentration of 0´1 mol/L EDTA in the case of C4) prior to electrophoresis in order to inhibit C3 and C4 activation (which has been found to occur during electrophoresis). 13 EDTA (to a ®nal concentration of 0´01 mol/L) was also added to the electrophoresis buffer (Beckman Barbital pH 8´6 buffer). Antisera to C3c and C4c were obtained from Dakopatts, Copenhagen and were applied undiluted. The speci®city of the antisera is such that it reacts with human C3c and C4c complement components as well as the native (intact) C3 and C4 complement molecules.
In vitro complement activation
The classical pathway of complement was activated by adding 20 mL of anti-albumin (Dakopatts) to 500 mL of fresh serum and incubating at 37°C for 30 minutes. 13 This specimen was then analysed for total C4 on the Beckman Array.
Addition of EDTA to fresh serum samples EDTA was added (to a ®nal concentration of 0´05 mol/L) to a number of serum samples from patients with HCV infection when they were fresh, and both treated and untreated serum samples were then analysed for total C4 on the Beckman Array after storage at 4°C.
Other investigations
Standard liver function tests [albumin, total bilirubin, alkaline phosphatase (ALP), g-glutamyl transferase (gGT), alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] were performed on the Beckman Synchron CX7. Rheumatoid factor (RF) was detected by nephelometry using the Dade Behring N Latex RF reagent (Dade Behring GMBH, Marburg, Germany). Cryoglobulin was determined by visual observation in serum samples that were stored for up to 7 days at 4°C. Antinuclear (ANA), anti-smooth muscle (ASM), anti-parietal cell (APC) and antimitochondrial (AMA) antibodies were detected by indirect immuno¯uorescence using`snap' frozen rat tissue as substrate and¯uorescein isothiocyanate-labelled anti-human globulin as conjugate. Hepatitis C virus RNA was determined in serum by reverse transcription polymerase chain reaction (RT-PCR) using a commercial kit (Roche Diagnostics, Lewis, UK). Antibodies to HCV were detected by an in vitro qualitative immunoblot assay (Chiron RIBA HCV 3.0 SIA) which utilizes two recombinant HCV-encoded antigens (NS5, c33c) and two synthetic HCV-encoded peptides (c100p, c22p) immobilized as individual bands onto test strips. Both HCV RNA (RT-PCR) and HCV antibody testing (RIBA) were carried out in the Virus Reference Laboratory, University College Dublin.
Statistical analysis
Frequencies of abnormal or positive test results occurring in CDAC and non-CDAC groups were compared by the w 2 test using Yates' correction.
RESULTS
Complement 4 levels increased (de®ned as an increase in C4 of 50´03 g/L) in 33 of the 63 serum specimens of patients with HCV infection (52%) after overnight storage at 4°C. This value of 0´03 g/L was chosen as the lowest value which could be considered a true increase, given the between-assay coef®cient of variation (2´1%) of the method. The increase in measured C4 levels ranged from 0´03±0´20 g/L (mean=0´06 gL) representing a percentage increase of 11±66% (mean=29%) (see Table 1 ). To a lesser extent, C3 levels also increased in these serum specimens [mean (standard deviation), fresh 0´98 (0´16) g/L; after storage 1´05 (0´182) g/L]. The increase in measured C3 levels ranged from 0´01±0´18 g/L (mean=0´07 g/L) representing a percentage increase of 0´9±16´1% (mean=6´6%). However, given the between-assay coef®cient of variation of 3%, a true increase in C3 (de®ned as 50´13 g/ L) was seen in only two of the 33 specimens (6%). In ®ve of the 33 serum specimens (15%), C4 levels were below the reference range when measured fresh but increased to levels within the reference range after overnight storage at 4°C. Similarly, in two of the 33 serum specimens (6%), C4 levels went from within the reference range to above the reference range after storage. In contrast, both C4 and C3 levels did not increase in any of the 63 EDTA specimens; nor did C3 levels increase in the serum specimens of patients with HCV infection, in whom C4 levels also did not increase. Furthermore, the increase in C4 levels, which did occur in serum specimens after storage at 4°C, could be prevented by the addition of EDTA (0´05 mol/L) prior to storage (see Table 2 ).
In vitro activation of complement by the addition of anti-albumin to fresh serum samples resulted in an increase in measured C4 levels in all cases (n=3) (mean, unactivated 0´26 g/L, after activation 0´31 g/L).
Immuno®xation of intact and activated C4 products, carried out on ®ve specimens in which C4 levels increased after overnight storage at 4°C, showed a mean 62´9% increase in activated products (range 50´4±72´6%) during storage, whereas in four specimens in which C4 levels were stable, the increase was minimal (mean 2´8%, range 0´4±5´5%) (see Table 3 and Fig. 1 ). Of note, in three of the ®ve specimens in which C4 levels increased, there was total activation of C4, i.e. no unactivated C4 was detected after storage. In contrast, C3 immuno®xation, carried out on seven specimens in which C4 increased after overnight storage, showed a much lower increase in activated products (mean 4´7%, range 1´4±10´5%), whereas in four specimens in which C4 levels were stable, virtually no further activation occurred on storage (i.e. range to 0´2%).
Complement analysis on the routine paired serum/EDTA specimens (n=36) showed similar results for C4, with C3 results being 7% lower in EDTA specimens. Linear regression analysis using Deming's correction of the paired data yielded the following equations (y=EDTA, x=serum):
In vitro cold activation of complement shown by an overestimation of total C4 689 In addition, C3 and C4 were found to be stable in EDTA specimens (including specimens from patients with hepatitis C virus infection) stored at 4°C for a minimum of 2 days. A comparison of various investigations carried out on patients in whose serum C4 levels increased after overnight storage at 4°C (i.e. in whose specimens CDAC had occurred, n=33) with those from patients in whose serum samples C4 levels remained stable (i.e. CDAC was absent, n=30) showed that there was no signi®cant difference between the incidence of abnormal liver function tests, the presence of autoantibodies ANA, ASM, APC and AMA, the incidence of abnormally low C3 and C4 levels as measured in the fresh EDTA specimens, frequency of patients testing positive for cryoglobulin, or antibody positivity to the NS5 viral antigen (see Table 4 ). However, the presence of hepatitis C viraemia (P< 0´0001), the frequency of patients testing positive for RF (P< 0´05) and the frequency of patients testing positive for HCV antibody against one or more of the antigens tested (RIBA; P< 0´05) was signi®cantly higher in the former group compared with the latter.
DISCUSSION
We have reported for the ®rst time that total C4 levels, when measured by the Beckman Array nephelometer, may increase in serum specimens after overnight storage at 4°C. This phenomenon is seen frequently in serum samples of patients with HCV infection, and the results of this study suggest it occurs when in vitro activation of complement (CDAC) takes place. This conclusion is based on four ®ndings. (1) In all 33 patients with HCV infection in whose serum samples C4 levels increased after storage at 4°C, the C4 levels remained the same after storage in the corresponding EDTA specimens. This ®nding ful®ls one of the conditions of CDAC, namely that complement activation is seen in chilled serum but not in the corresponding chilled EDTA plasma. (2) The increase in C4 levels which occurred in some serum specimens after overnight storage at 4°C was prevented by the prior addition of EDTA (0´05 mol/L) when the specimens were fresh. (3) In vitro activation of the classical pathway of complement by the addition of anti-albumin to three different serum specimens resulted in an increase in C4 levels being measured on the Array in each case. (4) Complements 3 and 4 immuno®xation con-®rmed that there was complement activation occurring in the specimens where C4 levels increased after storage at 4°C. The ®nding of a greater increase in C4 activation compared with that of C3 is similar to a report by Mathews et al. in which the percentage increase seen in C3a (a breakdown product of C3) was 9´5% as opposed to 97´4% for C4a (likewise a breakdown product of C4) in a specimen in which CDAC had occurred. 6 This ®nding of greater C4 activation is common in¯uid phase classical complement pathway activation (as opposed to that occurring on a cell membrane), since¯uid phase activation is inef®cient in the formation of the C3 convertase and thus very little activation of C3 occurs. 4, 6 It is not clear why complement activation results in an apparent increase of C4 being measured on the Beckman Array. In another study, in which total C4 levels were measured by nephelometric analysis (using Dade Behring BNA) the levels remained the same after in vitro activation of complement had taken place. 8 Beckman antisera is directed against native C4 and its major activation products and throughout the course of antibody production, Beckman aim to minimize the degree of complement activation, but do not routinely test for it (personal communication, 1996) . The increase seen on the Array may be related to differences in the speci®city or avidity of the Beckman antisera for native C4 and its activated products. Alternatively, it is conceivable that activation of complement in specimens stored at 4°C may expose additional antigenic sites that further react with the Beckman antisera.
The temperature at which CDAC occurs has been studied by Mathews et al. 6 They found that there was greater CDAC activity at 13°C than at 4°C, with minimal activation occurring at 24°C. In some of the serum samples from patients with HCV infection that we studied, C4 levels had started to increase in fresh serum stored at room temperature and then increased further after overnight storage at 4°C. We also found no further increase in C4 levels in specimens stored at 4°C after the initial overnight storage at 4°C (19 specimens tested, data not shown).
In addition to the obvious advantage of inhibiting in vitro complement activation, we found potassium EDTA plasma specimens to be suitable for analysis of C3 and C4 on the Beckman Array. Our ®ndings on complement levels in EDTA specimens are similar to that of Newell et al., who also found no difference in total C4 levels measured by nephelometry in serum and EDTA plasma but found total C3 levels to be 12% lower in EDTA plasma. 5 Various frequencies for CDAC positivity among patients with HCV infection have been reported in the literature, namely, 41% 10 , 76% 11 , 89% 12 and in our case 52%; these may occur as a result of different patient selection procedures. Although RF positivity is generally a relatively common ®nding in serum samples from patients with HCV infection, 14, 15 we have found that the frequency of patients testing positive for RF in the group where CDAC was present was signi®cantly higher than in the other group. We have also demonstrated for the ®rst time that the number of patients testing positive for HCV antibody (RIBA) was sig-ni®cantly higher in the former group and also that there was a higher frequency of positivity against antigens c100p, c33c and c22p. These ®ndings, together with the increased incidence of hepatitis C viraemia, would imply that an immune complex consisting of HCV and antibody or, alternatively, an HCV antibody (with or without HCV attached) complexed with RF could be responsible for the activation of complement at low temperatures. Further studies are needed to identify the factor(s) involved in CDAC in patients with HCV infection and whether the same factor is responsible in all cases.
In view of the above ®ndings on the phenomenon of CDAC and its particular`effect' on serum complement analysis on the Beckman Array, we would strongly recommend the use of EDTA plasma specimens when analysing complement levels on the Array in order to avoid the possibility of reporting falsely elevated levels of C4. 
